STOCK TITAN

Neuronetics Inc - STIM STOCK NEWS

Welcome to our dedicated news page for Neuronetics (Ticker: STIM), a resource for investors and traders seeking the latest updates and insights on Neuronetics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Neuronetics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Neuronetics's position in the market.

Rhea-AI Summary
Neuronetics, Inc. (STIM) grants 135,000 Restricted Stock Units to new non-executive employees as inducement awards. The RSUs vest over four years, subject to continued service with the company.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.83%
Tags
none
-
Rhea-AI Summary
Neuronetics, Inc. (NASDAQ: STIM) receives FDA clearance for NeuroStar Advanced Therapy as an adjunct treatment for major depressive disorder in adolescents aged 15-21. The therapy, the first and only of its kind for this age group, shows promising response rates and safety profile based on real-world data.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.35%
Tags
clinical trial
-
Rhea-AI Summary
Neuronetics, Inc. (NASDAQ: STIM) expands commercial partnership with Transformations Care Network, enhancing access to NeuroStar TMS therapy for patients suffering from major depressive disorder. The exclusive agreement aims to improve mental healthcare by providing innovative treatment options.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.24%
Tags
partnership
Rhea-AI Summary
Neuronetics, Inc. (NASDAQ: STIM) reports a successful fourth quarter and full year 2023, with revenue increases, positive cash flow, and operational milestones. The Company's NeuroStar Advanced Therapy system revenue, treatment session revenue, and global patient treatments show significant growth. The launch of the 'Better Me Guarantee Provider' pilot program and updates in healthcare policies further highlight Neuronetics' commitment to patient care and innovation.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
15.41%
Tags
earnings
-
Rhea-AI Summary
Neuronetics, Inc. (STIM) to release Q4 2023 financial results on March 5th, 2024. The conference call will be held at 8:30 a.m. ET. The Company focuses on improving neurohealth disorders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.26%
Tags
conferences earnings
-
Rhea-AI Summary
Neuronetics, Inc. (STIM) announces advancements to the TrakStar® Patient Data Management System, offering workflow efficiencies for NeuroStar® TMS providers. The update aims to streamline patient tracking and documentation for improved patient care processes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.33%
Tags
none
Rhea-AI Summary
Neuronetics, Inc. announced that Lucet Health has changed its criteria to increase access for patients with depression to receive transcranial magnetic stimulation (TMS), reducing the number of antidepressant medication attempts required prior to TMS eligibility. This policy update is effective as of February 1, 2024, and impacts approximately 9 million covered lives. Neuronetics also reported momentum for favorable TMS coverage changes through three additional payors, positioning the company as the only TMS company in the industry with a dedicated health policy team.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.67%
Tags
none
-
Rhea-AI Summary
Neuronetics, Inc. (NASDAQ: STIM) announced preliminary unaudited fourth quarter and full year 2023 results, with total revenue expected to be over $71 million for the year. The company also achieved positive cash flow of over $1 million in the fourth quarter, ending 2023 with cash and cash equivalents at approximately $59 million. Neuronetics is a commercial stage medical technology company focused on transforming the lives of patients with neurohealth therapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.35%
Tags
earnings
-
Rhea-AI Summary
Neuronetics, Inc. (NASDAQ: STIM) announced the FDA 510(k) clearance of NeuroSite™ Coil Placement Accessory, a tool that simplifies measurement and coil positioning during NeuroStar TMS treatments. The accessory integrates with both legacy and new NeuroStar systems, streamlining the TMS process with significantly fewer patient setup steps, improving efficiency for providers and enhancing the patient experience. NeuroSite™ will be available to all NeuroStar providers beginning in Q1 of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.4%
Tags
none
Rhea-AI Summary
Neuronetics, Inc. (NASDAQ: STIM) has received approval from the PMDA in Japan for multiple proprietary innovations that significantly advance the patient treatment experience with the NeuroStar TMS Therapy System for the treatment of major depressive disorder (MDD). The features covered in this approval include the NeuroStar 3.7 platform, MT Cap, D-Tect™ MT Accessory, and the Dash treatment protocol. The Dash treatment protocol reduces the daily TMS treatment time from 38 minutes to under 19 minutes. Neuronetics is committed to supporting patients and clinicians in Japan who are looking for treatments beyond medication, with an exclusive distribution partnership with Teijin Pharma Limited. The company aims to fill the unmet need for patients who have failed to achieve remission from depression through antidepressant medications. NeuroStar is also advancing its global strategy and strengthening its global presence with recent announcements of regulatory approval in South Korea, as well as EU-MDR and MDSAP certifications.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.87%
Tags
none
Neuronetics Inc

Nasdaq:STIM

STIM Rankings

STIM Stock Data

141.64M
22.83M
6.88%
60.59%
0.18%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
US
Malvern

About STIM

with neurostar advanced therapy, neuronetics, inc., is the market leader in transcranial magnetic stimulation technology for the treatment of major depressive disorder. based in malvern, pa, we are a privately held medical device company focused on developing non-invasive therapies for psychiatric and neurological disorders using mri-strength magnetic field pulses. we are the first company to have a non-systemic and non-invasive depression treatment cleared by the fda for patients who have not benefited from prior antidepressant medication. neuronetics markets neurostar advanced therapy throughout the united states and select markets around the world. if you have questions or comments about neurostar, please e-mail us at customersupport@neuronetics.com. for u.s. phone support, please call us at (877) 600-7555, for international customers, our number is +1 (610) 640-4207.